Press release
T-cell Engagers Market to Record US$ 58.04 billion by 2035., Growth by Projection (2026 ) - Genmab A/S, Xencor Inc., Merus N.V., Immunocore Holdings plc, Gilead Sciences Inc
T-cell Engagers Market Size 2026-2035
Global T-cell Engagers Market stood at US$ 7.27 billion in 2025 and is projected to reach US$ 58.04 billion by 2035, growing at a CAGR of 22.73% during 2026-2035.
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/t-cell-engagers-market?kb
United States: Recent Industry Developments
✅ March 2026: Amgen Inc. advanced next-generation BiTE (bispecific T-cell engager) platforms targeting solid tumors, strengthening clinical pipeline expansion in oncology immunotherapy.
✅ February 2026: Regeneron Pharmaceuticals expanded its bispecific antibody manufacturing capabilities to support late-stage development programs in hematologic malignancies and solid tumor indications.
✅ January 2026: Johnson & Johnson (Janssen) progressed collaborative studies on T-cell engager combinations with checkpoint inhibitors to enhance durable anti-tumor responses.
✅ December 2025: MacroGenics, Inc. accelerated clinical evaluation of novel CD3-based T-cell engagers focused on improving tumor selectivity and reducing off-target toxicity.
Ready to scale in the T-cell Engagers Market? connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/t-cell-engagers-market?kb
List of Key Players 2026:
Amgen Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Genmab A/S, AbbVie Inc., Pfizer Inc., and Regeneron Pharmaceuticals Inc.
Leading Companies 2026:
Immunocore Holdings plc, Astellas Pharma Inc., Xencor Inc., and Merus N.V. are focusing on differentiated T-cell redirection approaches, novel therapeutic targets, and advanced drug formulation technologies as part of their strategic initiatives.
Other Key Players 2026:
Bristol Myers Squibb Company, GSK plc, and Gilead Sciences Inc., are strengthening their market position through oncology-focused drug pipelines, strategic collaborations, and ongoing immunotherapy research and development initiatives.
Key Strategic Growth Forecast Projections 2026:
The Global T-cell Engagers Market is entering a high-growth phase, with strong momentum expected throughout 2026-2035. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
April 2026: Astellas Pharma and Vir Biotechnology entered into a global collaboration to develop VIR-5500, a PSMA-targeting dual-masked T-cell engager designed for prostate cancer treatment.
March 2026: Antengene out-licensed ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune diseases, to UCB for global development and commercialization.
February 2026: Boehringer Ingelheim and Zai Lab announced a strategic collaboration to develop a DLL3-targeting T-cell engager in combination with antibody-drug conjugate therapy.
January 2026: Johnson & Johnson expanded the clinical development of Tecvayli into earlier-line treatment settings for multiple myeloma through additional Phase III studies.
September 2025: Regeneron Pharmaceuticals secured FDA approval for linvoseltamab, a BCMA/CD3 T-cell engager indicated for relapsed multiple myeloma.
July 2025: Genmab and AbbVie expanded the clinical development of Epkinly through combination therapy trials targeting diffuse large B-cell lymphoma and follicular lymphoma.
May 2025: Pfizer advanced Elrexfio into wider global commercialization following expanded regulatory approvals across additional oncology markets.
How Our Market Research Process Works:
The global T-cell Engagers Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of T-cell Engagers adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• May 2026: UCB agreed to acquire Candid Therapeutics for up to $2.2B to expand its pipeline in next-generation T-cell engagers for autoimmune diseases
• May 2026: Gilead Sciences announced the acquisition of Ouro Medicines, strengthening its autoimmune-focused T-cell engager portfolio with BCMAxCD3 clinical-stage assets
• Jan 2026: Bristol Myers Squibb entered a collaboration with Janux Therapeutics worth up to $850M to develop tumor-activated T-cell engager therapies for solid tumors
• Jan 2026: Multiple pharma-biotech T-cell engager partnerships continued, with Janux advancing masked TCE platforms under expanded BMS development agreements
• Jan 2026: Eli Lilly strengthened immunology pipeline through broader autoimmune-focused deals aligned with T-cell based therapeutic platforms (TCE/bispecific expansion trend
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=t-cell-engagers-market?kb
Japan: Recent Industry Developments
✅ March 2026: Chugai Pharmaceutical Co., Ltd. (Roche Group) strengthened its bispecific antibody pipeline, focusing on T-cell engager therapies for oncology precision treatment.
✅ February 2026: Takeda Pharmaceutical Company expanded strategic collaborations to develop T-cell engager-based immunotherapies targeting rare and refractory cancers.
✅ January 2026: Astellas Pharma advanced clinical programs integrating T-cell engaging antibody platforms to enhance immune-mediated tumor cell killing.
✅ December 2025: Daiichi Sankyo accelerated research in next-generation antibody-drug and T-cell engager hybrid constructs for solid tumor applications.
Major Segments Opportunity 2026:
By Molecule Type: Bispecific T-cell Engagers, Trispecific T-cell Engagers, Multispecific T-cell Engagers, T-cell Receptor Based Engagers, Antibody Fragment Based T-cell Engagers, and Full-Length Antibody Based T-cell Engagers
By Target Antigen: CD19, CD20, CD22, CD33, BCMA, GPRC5D, HER2, EGFR, PSMA, DLL3, CEA, Claudin 18.2, Mesothelin, and Others
By Therapy Type: Monotherapy and Combination Therapy
By Indication: Cancer, Autoimmune Diseases, Infectious Diseases, Fibrotic Disorders, Immune Mediated Disorders, Transplant Rejection, Rare Diseases, and Others
By Mechanism of Engagement: T-cell Redirecting Engagers, Tumor Specific T-cell Activation, Conditional Activation T-cell Engagers, Immune Synapse Enhancing Engagers, and Cytotoxic T-cell Recruitment Platforms
By Administration Route: Intravenous, Subcutaneous, Intratumoral, and Continuous Infusion
By Development Stage: Discovery Stage, Preclinical Stage, Phase I, Phase II, Phase III, and Commercialized Products
By End User: Hospitals, Specialty Cancer Centers, Academic Research Institutes, Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, and Others
Regional Growth Intelligence for Market:
⇥ North America - Leads the T-cell engagers market due to strong presence of advanced oncology research, high adoption of immunotherapy treatments, and robust clinical trial activity.
⇥ Europe - Significant market supported by growing investment in cancer immunotherapy, expanding biopharmaceutical R&D, and increasing regulatory approvals.
⇥ Asia-Pacific - Rapidly growing region driven by rising cancer burden, improving healthcare infrastructure, and expanding access to novel biologics.
⇥ Latin America - Emerging market with increasing adoption of advanced oncology therapies and gradual expansion of specialty cancer treatment centers.
⇥ Middle East & Africa - Developing region with growing oncology awareness, improving hospital infrastructure, and increasing access to targeted immunotherapies.
Request Strategic Market Customization: https://datamintelligence.com/customize/t-cell-engagers-market?kb
FAQ's:
Q1: What is the current size of the T-cell Engagers Market?
A: The T-cell Engagers Market was valued at US$ 7.27 billion in 2025 and is projected to reach US$ 58.04 billion by 2035
Q2: How rapidly is the Market expanding?
A: The T-cell Engagers Market is expected to grow at a CAGR of 22.73% during the forecast period 2026 to 2035
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release T-cell Engagers Market to Record US$ 58.04 billion by 2035., Growth by Projection (2026 ) - Genmab A/S, Xencor Inc., Merus N.V., Immunocore Holdings plc, Gilead Sciences Inc here
News-ID: 4518846 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Nanotechnology Market to Reach USD 338.16 Billion by 2033 Driven by Advances in …
The global nanotechnology market is experiencing substantial growth as industries increasingly adopt nanoscale materials and technologies to improve product performance, efficiency, durability, and innovation across multiple sectors.
According to DataM Intelligence, the global nanotechnology market was valued at approximately USD 112.28 billion in 2025 and is projected to reach nearly USD 338.16 billion by 2033, growing at a CAGR of 15.8% during the forecast period from 2026 to 2033.
Get Exclusive Market…
Surveillance Radar Market to Reach US$ 9.86 Billion by 2033 Amid Rising Defense …
The global surveillance radar market is witnessing steady growth as governments and defense agencies worldwide increase investments in advanced radar systems to strengthen national security, border surveillance, maritime monitoring, and airspace management.
According to DataM Intelligence, the Surveillance Radar market reached US$ 5.65 billion in 2025 to US$ 6.05 billion in 2026 and is expected to reach US$ 9.86 billion by 2033, growing with a CAGR of 7.2% during the forecast…
Multiple Myeloma Market Expected to Reach US$ 34.58 Billion by 2032 as Advanced …
DataM Intelligence has released a new research report titled "Multiple Myeloma Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms…
Smart Cities Market to Reach USD 2,261.0 Billion by 2033 Driven by Urban Digital …
The global smart cities market is witnessing rapid expansion as governments and urban planners increasingly invest in digital infrastructure, intelligent transportation systems, sustainable energy management, and connected urban ecosystems to improve quality of life and operational efficiency.
According to DataM Intelligence, the Smart Cities Market is estimated to reach USD 699.7 Billion in 2025 and is projected to grow to USD 2,261.0 Billion by 2033, registering strong growth at a CAGR…
More Releases for Engagers
Leading Companies Fueling Innovation and Growth in the Bispecific T-Cell Engager …
The bispecific T-cell engagers market is positioned for remarkable growth in the coming years, driven by numerous advancements and expanding clinical applications. As the field of cancer immunotherapy evolves, these innovative therapies are becoming increasingly vital in targeting difficult-to-treat malignancies. Let's explore the market's size projections, key players, ongoing trends, and market segments shaping its promising future.
Projected Growth and Expansion of the Bispecific T-Cell Engagers Market
The bispecific T-cell…
Bispecific T-Cell Engagers (BiTEs) Market to Reach US$15.55 Billion by 2033, Exp …
The global Bispecific T-cell Engagers (BiTEs) market size reached US$ 2.10 billion in 2024 (from US$ 1.68 billion in 2023) and is expected to reach US$ 15.55 billion by 2033, growing at a CAGR of 25.1% from 2025 to 2033, according to DataM Intelligence.
United States: Recent Industry Developments
✅ In October 2025, Amgen expanded distribution of Blincyto (blinatumomab) to a majority of U.S. oncology centers and hospital systems, enhancing access for…
Immune Cell Engagers Market Innovation in Conditional Activation and Safety Engi …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Immune Cell Engagers (ICEs) Market Size, Share & Trends Analysis Report By Product Type (Bispecific Antibodies, Trispecific/Multispecific Antibodies, Engineered Cell Therapies), By Target Antigen (Oncology Targets, Autoimmune/Inflammatory Targets), By Mechanism of Action (Immune Cell Recruitment, Signal Modulation, Conditional Activtion), By Therapeutic Area (Oncology, Autoimmune/Inflammatory), Development Stage (Clinical Phase, Marketed/Approved),-Market Outlook And Industry Analysis 2035"
Immune…
Global T-cell Engagers Market to Surpass USD 20.1 Billion by 2035, Growing at 22 …
The global T-cell Engagers Market, valued at USD 2.2 billion in 2024, is projected to grow at an exceptional CAGR of 22.3% from 2025 to 2035, reaching USD 20.1 billion by the end of 2035, according to the latest industry analysis. This surge reflects the accelerating pace of innovation in immuno-oncology, the rise of bispecific antibody platforms, and expanding clinical success across hematologic and solid tumor indications.
T-cell engagers represent a…
T Cell Engagers Market Poised for Explosive Growth: Unveiling Key Trends and Bus …
The latest comprehensive study on the T Cell Engagers Market by Worldwide Market Reports offers an in-depth exploration of industry dynamics, emerging trends, and market shifts that are shaping the future of global commerce. Crafted for a professional audience spanning the USA, UK, South Korea, and other key regions, this report delivers actionable intelligence to help organizations navigate uncertainty and seize new growth opportunities.
➤ This robust research draws from validated…
Bispecific T-cell Engagers (BiTEs) Market Size, Clinical Trials, Product Pipelin …
Bispecific T-cell Engagers (BiTEs) Market Size is estimated to be $5450 million in 2024 and is expected to grow at an average yearly rate of around 8% during the timeframe (2025-2032).
What is Bispecific T-cell Engagers (BiTEs) and what are the growth drivers of Bispecific T-cell Engagers (BiTEs) Market?
Bispecific T-cell Engagers, commonly known as BiTEs, are a novel class of immunotherapy drugs designed to harness the…
